Discovery of Prodrug of MRTX1133 as an Oral Therapy for Cancers with KRAS G12D Mutation
ACS Omega · 21.02.2023 · 8 (7) · 7211-7221
DOI: 10.1021/acsomega.3c00329 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Omega, online erschienen am 09.02.2023. Verfasst von Xiang Ji und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, School of Life Sciences, Fudan University, Shanghai 200437, China. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Risen (Shanghai) Pharmaceutical Technology Co. Ltd..
Abstract (Originalsprache)
Effective oral therapies are urgently required to treat KRASG12D mutant cancers. Therefore, synthesis and screening were performed for 38 prodrugs of MRTX1133 to identify an oral prodrug of MRTX1133, a KRASG12D mutant protein-specific inhibitor. In vitro and in vivo evaluations revealed prodrug 9 as the first orally available KRASG12D inhibitor. Prodrug 9 exhibited improved pharmacokinetic properties for the parent compound in mice and was efficacious in a KRASG12D mutant xenograft mouse tumor model after oral administration.
Autor:innen und Institutionen
- Department of Biochemistry, School of Life Sciences, Fudan University, Shanghai 200437, China.
- Risen (Shanghai) Pharma Tech Co., Ltd., Shanghai 201210, China.
- Guangdong Key Laboratory of Nanomedicine, Chinese Academy of Sciences, Shenzhen 518055, China.
ORCID-Profile: Xiang Ji
Förderung
- Risen (Shanghai) Pharmaceutical Technology Co. Ltd.
Zitieren
APA
Ji, X., Li, Y., Kong, X., Chen, D., & Lu, J. (2023). Discovery of Prodrug of MRTX1133 as an Oral Therapy for Cancers with KRAS G12D Mutation. ACS Omega, 8(7), 7211-7221. https://doi.org/10.1021/acsomega.3c00329
Vancouver
Ji X, Li Y, Kong X, Chen D, Lu J. Discovery of Prodrug of MRTX1133 as an Oral Therapy for Cancers with KRAS G12D Mutation. ACS Omega. 2023;8(7):7211-7221. doi:10.1021/acsomega.3c00329
BibTeX
@article{Ji2023,
author = {Ji, Xiang and Li, Yan and Kong, Xianqi and Chen, Dawei and Lu, Jiasheng},
title = {Discovery of Prodrug of MRTX1133 as an Oral Therapy for Cancers with KRAS G12D Mutation},
journal = {ACS Omega},
year = {2023},
volume = {8},
number = {7},
pages = {7211--7221},
doi = {10.1021/acsomega.3c00329}
}
EUVIMED